Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Fiscal Year: January - December
Johnson & Johnson (JNJ), listed on the NYSE, has a market capitalization of $. As of Feb 21, 2026, the stock is trading at $242.49 per share, offering investors a clear view of its current market value. Johnson & Johnson is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 21.98, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Johnson & Johnson also offers a dividend yield of 2.14%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Johnson & Johnson (JNJ) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Johnson & Johnson is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Johnson & Johnson, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Johnson & Johnson is 29.82, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Johnson & Johnson (JNJ) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Johnson & Johnson (JNJ) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Johnson & Johnson (JNJ) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Johnson & Johnson. To access the full SS Score, consider upgrading your subscription.
Johnson & Johnson is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 21.98. Investors should compare these metrics with industry peers to gauge whether Johnson & Johnson is outperforming or underperforming within its sector.
Q4 Healthcare Dividends: Johnson & Johnson Kept Outshining Pfizer (Rating Upgrades)
Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO™; results surpass current standards of care RARITAN, N.J., Feb. 19, 2026 /PRNewswire/ -- Johnson & Jo...
Johnson & Johnson is preparing a potential sale of the orthopedics unit that it has been planning to separate, with big buyout firms already circling, Bloomberg News reported on Thursday, citing peopl...
Johnson & Johnson announced a $1 billion investment in a Montgomery County, Pennsylvania, cell therapy facility that will yield over 500 manufacturing jobs plus 4,000 construction jobs.
The facility is part of the company's plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.
Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale up U.S. manufacturin...
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment i...
New designation is based on data showing rapid and durable responses in a heavily pretreated patient population and expands the promise of RYBREVANT FASPRO™ beyond lung cancer RARITAN, N.J., Feb. 18, ...
Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ ...
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, divide...
The plaintiff used J&J's baby powder from 1969 until 2017. She sued in 2019 and died six months later at the age of 68.
PHILADELPHIA--(BUSINESS WIRE)--A jury in the Philadelphia Court of Common Pleas has found Johnson & Johnson (NYSE:JNJ) responsible for the company's baby powder products contributing to the death of a...
A jury in Pennsylvania state court on Friday awarded $250,000 to the family of a woman who sued Johnson & Johnson alleging its talc-based baby powder was to blame for her ovarian cancer, according to ...
Johnson & Johnson (JNJ) stock is currently at a notable juncture. It exhibits strong momentum, up 55% in the last twelve months, and investing in it entails support for a company characterized by robu...
The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA stroke prevention trial.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10th, 2026. Management will participate in a...
IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study and highlighted new findings related to the VARIPULSE Platform.
The industrials sector has been a big beneficiary of the rotation out of tech, with a number of defense and transportation stocks hitting new highs on Wednesday.
In the nearly nine months spanning from May 2025 to February 2026, Johnson & Johnson (JNJ)'s stock experienced a remarkable 52% increase, driven by improved earnings, significant product achievements,...
World's #1 Selling Contact Lens Brand ACUVUE®*1 Brings Pioneering Innovation For Astigmatic Patients With Presbyopia, Providing Visual Clarity And Comfort**2
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3rd, 2026. Management will participate in a Firesi...
Barrick Mining Corporation's solid liquidity supports its commitment to shareholder returns, reflected in increased share repurchases and a raise in its quarterly dividend. Johnson & Johnson's perform...
Johnson & Johnson: Fraud Claim Dismissal Today Is Not A Sign Talc Litigation Is Over
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2026 | 25.14B | Analyst x3 | |
| 2027 | 26.35B | 4.84% | Analyst x4 |
| 2028 | 29.03B | 10.17% | Analyst x3 |
| 2029 | 33.87B | 16.65% | Analyst x2 |
| 2030 | 36.45B | 7.62% | Analyst x2 |
| 2031 | 38.02B | 4.31% | Est @4.3% |
| 2032 | 39.46B | 3.79% | Est @3.8% |
| 2033 | 40.81B | 3.42% | Est @3.4% |
| 2034 | 42.01B | 2.95% | Est @2.9% |
| 2035 | 43.18B | 2.78% | Est @2.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 19.84B | 1.00 | 19.84B |
| 2025A | 19.70B | 1.00 | 19.70B |
| 2026E | 25.14B | 1.08 | 23.34B |
| 2027E | 26.35B | 1.16 | 22.72B |
| 2028E | 29.03B | 1.25 | 23.23B |
| 2029E | 33.87B | 1.35 | 25.16B |
| 2030E | 36.45B | 1.45 | 25.14B |
| 2031E | 38.02B | 1.56 | 24.35B |
| 2032E | 39.46B | 1.68 | 23.46B |
| 2033E | 40.81B | 1.81 | 22.53B |
| 2034E | 42.01B | 1.95 | 21.53B |
| 2035E | 43.18B | 2.10 | 20.54B |
| Terminal | 849.32B | 2.10 | 404.07B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.